Seek Returns

ARGX vs. GILD: argenx vs. Gilead Sciences Stock Comparison

How do argenx (ARGX) and Gilead Sciences (GILD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

argenx (ARGX) and Gilead Sciences (GILD) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Gilead Sciences (GILD) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for argenx (ARGX) and Gilead Sciences (GILD)
Profile ItemARGXGILD
Nameargenx SE American Depositary ReceiptGilead Sciences Inc.
Country/RegionNetherlandsUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization58.31 billion USD207.00 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateMay 18, 2017January 22, 1992
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

ARGX
GILD
GSPC
Loading price history…
argenx (ARGX) vs. Gilead Sciences (GILD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for argenx (ARGX) and Gilead Sciences (GILD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for argenx (ARGX) and Gilead Sciences (GILD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for argenx (ARGX) and Gilead Sciences (GILD)
MetricARGXGILD
Total Return (1Y)11.91%45.69%
Total Return (3Y, Annualized)25.68%35.30%
Total Return (5Y, Annualized)24.22%25.00%

Risk Profile

Drawdown History

ARGX
GILD
GSPC
Loading price history…
argenx (ARGX) vs. Gilead Sciences (GILD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for argenx (ARGX) and Gilead Sciences (GILD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for argenx (ARGX) and Gilead Sciences (GILD)
MetricARGXGILD
Volatility (1Y, Annualized)37.87%27.57%
Beta (5Y)0.450.36
Max Drawdown (5Y)-38.20%-26.59%
Avg. Volume (3M)359.84K5.98M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ARGX and GILD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for argenx (ARGX) and Gilead Sciences (GILD)
MetricARGXGILD
Sharpe Ratio (1Y)0.201.50
Sortino Ratio (1Y)0.312.48

Profitability

ROE (TTM)

argenx (ARGX) has no ROE value reported for this period; Gilead Sciences (GILD) reports a negative figure of -22.45%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
ARGX
--

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-22.45%

Max
109.18%
Q3
6.23%
GILD
-22.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
argenx (ARGX) vs. Gilead Sciences (GILD): ARGX does not report ROE, so it has no value marker; GILD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile argenx (ARGX) reports 31.73%, ranking against industry peers normally.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.73%

ARGX
31.73%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.46%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
GILD
-12.46%
Min
-17.05%
Loading chart…
argenx (ARGX) vs. Gilead Sciences (GILD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both argenx (ARGX) at 36.27% and Gilead Sciences (GILD) at 42.43% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.27%

Max
83.12%
ARGX
36.27%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.43%

Max
83.12%
GILD
42.43%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
argenx (ARGX) vs. Gilead Sciences (GILD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for argenx (ARGX) and Gilead Sciences (GILD)
MetricARGXGILD
ROE (TTM)---22.45%
ROA (TTM)--13.47%
Net Margin (TTM)31.73%-12.46%
Operating Margin (TTM)36.27%42.43%
Gross Margin (TTM)59.84%79.95%

Growth

Revenue Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Gilead Sciences (GILD) at 2.39% is closer to the peer norm — faster top-line expansion for ARGX.

Loading chart…
argenx (ARGX) vs. Gilead Sciences (GILD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Gilead Sciences (GILD) at 1,684.21% clears its industry range for EPS growth, a much stronger earnings trajectory than argenx (ARGX) at 53.13%, which is closer to a typical peer reading.

Loading chart…
argenx (ARGX) vs. Gilead Sciences (GILD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for argenx (ARGX) and Gilead Sciences (GILD)
MetricARGXGILD
Revenue Growth (YoY)89.64%2.39%
Revenue Growth (3Y CAGR)116.25%2.57%
EPS Growth (YoY)53.13%1,684.21%
EPS Growth (3Y CAGR)--23.04%

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: Gilead Sciences (GILD) shows current ratio of 1.38 against its industry benchmark, while argenx (ARGX) has no reading this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
Min
0.10
ARGX
--

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GILD
1.38
Min
0.10
Loading chart…
argenx (ARGX) vs. Gilead Sciences (GILD): ARGX does not report current ratio, so it has no value marker; GILD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

argenx (ARGX) at 0.01 keeps leverage in the lower quartile, while Gilead Sciences (GILD) at 2.02 is above its industry debt-to-equity ratio range.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
ARGX
0.01
Min
0.00

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.02

GILD
2.02
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
argenx (ARGX) vs. Gilead Sciences (GILD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for argenx (ARGX) and Gilead Sciences (GILD)
MetricARGXGILD
Current Ratio (MRQ)--1.38
Debt / Equity (MRQ)0.012.02
Net Debt / EBITDA-2.701.25

Dividends

Dividend Yield (TTM)

argenx (ARGX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a yield of 1.94%, ranking against industry peers normally.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

GILD
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
argenx (ARGX) vs. Gilead Sciences (GILD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

argenx (ARGX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Gilead Sciences (GILD) reports a payout of 43.46%, ranking against industry peers normally.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.46%

GILD
43.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
argenx (ARGX) vs. Gilead Sciences (GILD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for argenx (ARGX) and Gilead Sciences (GILD)
MetricARGXGILD
Dividend Yield (TTM)0.00%1.94%
Dividend Payout Ratio (TTM)0.00%43.46%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: argenx (ARGX) trades at 32.12 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.12

Max
85.34
Q3
43.46
ARGX
32.12
Median
26.69
Q1
13.30
Min
0.07

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
GILD
--
Loading chart…
argenx (ARGX) vs. Gilead Sciences (GILD): GILD does not report P/E ratio, so it has no value marker; ARGX is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both argenx (ARGX) at 9.86 and Gilead Sciences (GILD) at 6.68 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.86

Max
58.18
Q3
25.77
ARGX
9.86
Median
7.30
Q1
3.01
Min
0.01

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
GILD
6.68
Q1
3.01
Min
0.01
Loading chart…
argenx (ARGX) vs. Gilead Sciences (GILD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Measured against book value, both argenx (ARGX) at 172.23 and Gilead Sciences (GILD) at 15.88 look expensive — each P/B ratio sits above its industry’s benchmark range.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

172.23

ARGX
172.23
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.88

GILD
15.88
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
argenx (ARGX) vs. Gilead Sciences (GILD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for argenx (ARGX) and Gilead Sciences (GILD)
MetricARGXGILD
P/E Ratio (TTM)32.12--
P/S Ratio (TTM)9.866.68
P/B Ratio (MRQ)172.2315.88
Free Cash Flow Yield (TTM)--5.16%